Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Holding LYRA?
Track your performance easily
LYRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.16 - $6.79
Previous Close$0.18
Volume1.88M
Average Volume (3M)1.45M
Market Cap
$11.91M
Enterprise Value-$4.37M
Total Cash (Recent Filing)$51.60M
Total Debt (Recent Filing)$35.32M
Price to Earnings (P/E)―
Beta0.95
Next Earnings
Mar 05, 2025EPS Estimate
-$0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding65,457,648
10 Day Avg. Volume3,780,433
30 Day Avg. Volume1,446,255
Standard Deviation0.25
R-Squared0.00004
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.57
Price to Sales (P/S)8.71
Price to Cash Flow (P/CF)-0.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.97
Enterprise Value/Gross Profit-2.80
Enterprise Value/Ebitda0.04
Forecast
1Y Price Target
$2.00Price Target Upside958.20% Upside
Rating ConsensusHold
Number of Analyst Covering2
Lyra Therapeutics News
Bulls Say, Bears Say
Bulls Say
Financial PerformanceLYRA reported better than expected financial performance, with an EPS of $(0.18) versus consensus of $(0.22), showcasing strong financial health.
Safety ProfileSupportive safety data from the ENLIGHTEN-1 study shows LYR-210 is well tolerated with consistent results over a 12-month treatment period, indicating a strong safety profile.
Therapeutic EffectivenessSubgroup analysis demonstrated a statistically significant benefit on the 3CS scale for polyp patients, suggesting LYR-210 is effective in treating more severe disease.
Bears Say
Clinical TrialsThe LYR-210 Phase 3 ENLIGHTEN-1 trial in surgically naïve CRS patients demonstrated failure to reach the primary endpoint for 3 cardinal symptoms (3CS) score, the Sino-Nasal Outcome Test (SNOT-22) score, and ethmoid sinus opacification with CT scans.
Financial PerformanceThe company reported net loss of $11.9M, or $0.18/share for 3Q24.
Regulatory ApprovalThe regulatory path ahead is seen as unclear given the miss on one of two pivotal Phase 3 studies for LYR-210.
---
Ownership Overview
7.25% Insiders
3.89% Mutual Funds
25.91% Other Institutional Investors
55.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
LYRA FAQ
What was Lyra Therapeutics’s price range in the past 12 months?
Lyra Therapeutics lowest stock price was $0.16 and its highest was $6.79 in the past 12 months.
What is Lyra Therapeutics’s market cap?
Currently, no data Available
When is Lyra Therapeutics’s upcoming earnings report date?
Lyra Therapeutics’s upcoming earnings report date is Mar 05, 2025 which is in 102 days.
How were Lyra Therapeutics’s earnings last quarter?
Lyra Therapeutics released its earnings results on Nov 12, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.215 by $0.035.
Is Lyra Therapeutics overvalued?
According to Wall Street analysts Lyra Therapeutics’s price is currently Undervalued.
Does Lyra Therapeutics pay dividends?
Lyra Therapeutics does not currently pay dividends.
What is Lyra Therapeutics’s EPS estimate?
Lyra Therapeutics’s EPS estimate is -$0.13.
How many shares outstanding does Lyra Therapeutics have?
Lyra Therapeutics has 65,457,650 shares outstanding.
What happened to Lyra Therapeutics’s price movement after its last earnings report?
Lyra Therapeutics reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.215. Following the earnings report the stock price went down -28.571%.
Which hedge fund is a major shareholder of Lyra Therapeutics?
Among the largest hedge funds holding Lyra Therapeutics’s share is Perceptive Advisors LLC. It holds Lyra Therapeutics’s shares valued at 3M.
---
Lyra Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$2.00 (958.20% Upside)
$2.00 (958.20% Upside)
Blogger Sentiment
Bullish
LYRA Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-94.19%
12-Months-Change
Fundamentals
Return on Equity
-186.18%
Trailing 12-Months
Asset Growth
-34.68%
Trailing 12-Months
Company Description
Lyra Therapeutics
Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.
---
LYRA Stock 12 Month Forecast
Average Price Target
$2.00
▲(958.20% Upside)
Technical Analysis
---